Paul Jeng
Stock Analyst at Guggenheim
(2.95)
# 1,364
Out of 5,150 analysts
7
Total ratings
100%
Success rate
47.61%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Paul Jeng
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IDYA IDEAYA Biosciences | Reiterates: Buy | $50 | $34.68 | +44.18% | 2 | Feb 18, 2026 | |
| ADAG Adagene | Initiates: Buy | $9 | $2.93 | +207.17% | 1 | Nov 24, 2025 | |
| IMTX Immatics | Maintains: Buy | $16 → $19 | $10.18 | +86.64% | 2 | Nov 18, 2025 | |
| IMCR Immunocore Holdings | Assumes: Neutral | n/a | $33.73 | - | 1 | Sep 18, 2025 | |
| CNTX Context Therapeutics | Initiates: Buy | $5 | $2.60 | +92.31% | 1 | Sep 18, 2025 |
IDEAYA Biosciences
Feb 18, 2026
Reiterates: Buy
Price Target: $50
Current: $34.68
Upside: +44.18%
Adagene
Nov 24, 2025
Initiates: Buy
Price Target: $9
Current: $2.93
Upside: +207.17%
Immatics
Nov 18, 2025
Maintains: Buy
Price Target: $16 → $19
Current: $10.18
Upside: +86.64%
Immunocore Holdings
Sep 18, 2025
Assumes: Neutral
Price Target: n/a
Current: $33.73
Upside: -
Context Therapeutics
Sep 18, 2025
Initiates: Buy
Price Target: $5
Current: $2.60
Upside: +92.31%